Onkologie. 2009:3(5):281-284

The role of radiotherapy in lung cancer treatment

Milada Zemanová
Onkologická klinika 1. LF UK a VFN v Praze

Radiotherapy plays a crucial role in the treatment of lung cancer, whether designed as part of a potentially curative treatment plan or

intended as palliative therapy to suppress symptoms such as haemoptysis, dyspnoea due to bronchial obstruction, or chronic pain.

Radiotherapy, with either curative or palliative intent, should be used for the treatment of up to 76 % of all patients at some stage of

the disease, while, in the Czech Republic, only 20–24 % of lung cancer patients actually receive radiotherapy every year. Radiotherapy

is particularly useful in locally advanced, inoperable stage, but with the recent technological advances allowing for an extended therapeutic

window in terms of higher efficacy and lower toxicity, it has been indicated in earlier stages as well. To optimise the therapeutic

procedure in every patient, a radiotherapist should be a member of the multidisciplinary diagnostic-therapeutic team and take part in

decision making about the treatment strategy at the very beginning of the treatment.

Keywords: lung cancer, radiotherapy, chemoradiotherapy.

Published: December 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zemanová M. The role of radiotherapy in lung cancer treatment. Onkologie. 2009;3(5):281-284.
Download citation

References

  1. Novotvary 2005 ČR, ÚZIS ČR 2008.
  2. Delaney G, Barton M, Jacob S, Jalaludin B. Model rozhodování o zařazení radioterapie do léčby karcinomu plic. Lancet Oncology - české vydání. 2003; 2: 141-151.
  3. Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001 Mar 15; 49(4): 973-985. Go to original source... Go to PubMed...
  4. Wisnivesky JP, Bonomi M, Henschke C, Iannuzzi M, McGinn T. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest. 2005 Sep; 128(3): 1461-1467. Go to original source... Go to PubMed...
  5. Boffa DJ, Allen MS, Grab JD, et al. Data from The Society of Thoracic surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg. 2008; 135(2): 247-254. Go to original source... Go to PubMed...
  6. Timmerman RD, Park C, Kavanagh BD. The North American Experience with Stereotactis Body Radiation Therapy in Non-small Cell Lung Cancer. J Thorac Oncol 2007; 2(suppl 3): S101-S112. Go to original source... Go to PubMed...
  7. Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu CS, Mohan R, Cox JD, Komaki R. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1399-407. Go to original source... Go to PubMed...
  8. Lee CB, Stinchcombe TE, Rosenman JG, Socinski MA. Therapeutic advances in local-regional therapy for stage III nonsmall-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer. 2006 Nov;8(3):195-202. Review. Go to original source... Go to PubMed...
  9. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999 Aug; 52(2): 137-148. Go to original source... Go to PubMed...
  10. Baumann M, Herrmann T, Koch R, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated vs conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Eur J Cancer Suppl. 7, 2009; (3):4 (4LBA). Go to original source...
  11. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4; 323(14): 940-945. Go to original source... Go to PubMed...
  12. Le Chevalier T, Auperin A, Burdett S, et al. Sequential radiochemotherapy versus radiotherapy alone and concomitant radiochemotherapy versus radiotherapy alone in locally advanced non-small cell lung cancer (NSCLC): Two meta-analyses using individual patient data from randomized clinical trials. J Thorac Oncol 2007, 2(suppl 4): 1-04 S 309. Go to original source... Go to PubMed...
  13. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Efects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992 Feb 20; 326(8): 524-530. Go to original source... Go to PubMed...
  14. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699. Go to original source... Go to PubMed...
  15. Curran WJ, et al. Proc Am Soc Clin Oncol. 2003; 22: 621. Abstract 2499, RTOG 9410.
  16. Zatloukal P, Petruželka L, Zemanová M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer, 2004; 46, 1: 87-98. Go to original source... Go to PubMed...
  17. Aupérin A, Le Péchoux C, Pignon JP, et al. Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006 Mar; 17(3): 473-483. Go to original source... Go to PubMed...
  18. Postoperative radiotherapy for non-small cell lung cancer. PORT Meta-analysis Trialists Group. [No authors listed] Cochrane Database Syst Rev. 2000; (2): CD002142. Review. Update in: Cochrane Database Syst Rev. 2003; (1): CD002142.
  19. Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006; 24: 2998-3006. Go to original source... Go to PubMed...
  20. Falk SJ, Girling DJ, White RJ, et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial.; Medical Research Council Lung Cancer Working Party. BMJ. 2002 Aug 31; 325(7362): 465. Go to original source... Go to PubMed...
  21. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999 Jan 28; 340(4): 265-271. Go to original source... Go to PubMed...
  22. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 Aug 12; 341(7): 476-484. Go to original source... Go to PubMed...
  23. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. EORTC Radiation Oncology Group and Lung Cancer Group. N Engl J Med. 2007 Aug 16; 357(7): 664-672. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.